What do systematic reviews say?

Adjunctive carbamazepine + antipsychotics vs placebo/no adjunctive treatment + antipsychotics

It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).

• Carbamazepine for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 0.47 [0.16, 1.35]
  8 studies · 182 participants
  Very low

Perazine vs placebo

It is very uncertain whether perazine changes acceptability of treatment Leaving the study early due to any reason compared with placebo (very low certainty).

• Perazine for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 0.62 [0.35, 1.1]
  1 study · 95 participants
  Very low

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).

• Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 1 [0.88, 1.14]
  6 studies · 1532 participants
  Moderate

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

• Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).

• Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 0.78 [0.35, 1.76]
  3 studies · 323 participants
  Very low

Maintenance treatment with antipsychotic drugs vs placebo/no treatment

Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).

• Maintenance treatment with antipsychotic drugs for schizophrenia 2020 · Cochrane Headline outcomes only
  RR 0.54 [0.49, 0.61]
  56 studies · 7001 participants
  High

ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs placebo/no adjunctive treatment + antipsychotics

It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).

• Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
  RR 1.36 [0.81, 2.3]
  19 studies · 1185 participants
  Very low

BENZODIAZEPINES AS SOLE TREATMENT vs placebo

It is very uncertain whether BENZODIAZEPINES AS SOLE TREATMENT changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO (very low certainty).

• Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
  RR 0.89 [0.57, 1.38]
  8 studies · 440 participants
  Very low

Benzodiazepines vs antipsychotics

It is very uncertain whether BENZODIAZEPINES changes leaving the study early due to any reason (overall acceptability of… compared with ANTIPSYCHOTICS (very low certainty).

• Benzodiazepines for schizophrenia 2012 · Cochrane Headline outcomes only
  RR 0.73 [0.45, 1.18]
  13 studies · 738 participants
  Very low

TRIFLUOPERAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).

• Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 1.25 [0.72, 2.17]
  3 studies · 239 participants
  Low